Arvinas presents preclinical data on BCL6 degrader ARV-393 in lymphoma
ARVN•Arvinas presented preclinical data on its BCL6 degrader ARV-393 in lymphoma. Its Phase 1 trial is enrolling patients for monotherapy or combination treatment with glofitamab.
1. ARV-393 trial
Arvinas said its Phase 1 trial of ARV-393 is enrolling lymphoma patients for monotherapy treatment or combination treatment with glofitamab.
2. Company updates
The brief says Arvinas’ VEPPANU (vepdegestrant) received FDA approval on May 1, 2026, and commercial availability began in August after Rigel licensed the drug. Arvinas’ cash runway extends into the second half of 2028, and its clinical-stage partnerships with Pfizer and Novartis have generated more than $800 million.
